Transition from Squamous Cell Carcinoma to Adenocarcinoma in Adenosquamous Carcinoma of the Lung

Hironobu Kanazawa,* Masahito Ebina,* Nozomu Ino-oka,* Minoru Shimizukawa,* Toru Takahashi,† Shigefumi Fujimura,‡ Tadashi Imai,§ and Toshihiro Nukiwa*

From the Departments of Respiratory Oncology, Pathology, and Thoracic Surgery;‡ Institute of Development, Aging and Cancer, Tohoku University, Sendai; and the Department of Thoracic Surgery,§ Central Hospital of Aomori Prefecture, Aomori, Japan

The heterogeneity of tumor cells is frequently observed in lung cancer, but the clonality of these cells has not yet been established. The distinct components of 12 lung adenosquamous carcinomas were compared by genetic alterations of p53 and K-ras, chromosomal abnormalities at 9p21 and 9q31–32, and immunohistochemical reactions. The immunoreactivity of p53 was consistent in both adenosquamous- and squamous cell carcinomatous components as well as in the transitional areas, retaining the morphological characteristics of the distinct components. The same p53 mutation was found in both components of each tumor with p53 overexpression. No K-ras mutations were detected in any of the tumors examined. Three of the four tumors with chromosomal abnormalities detected, one at 9p21 and two at 9q31–32, had coincident abnormalities between the distinct components, whereas one tumor deleted homozygously at 9p21 (D9S259) in the adenosquamous component with loss of heterozygosity in the other component. The expression of squamous cell carcinoma-related antigen in adenosquamous cancerous components was significantly higher than that of lung adenocarcinomas (57 ± 5.8% vs. 1.0 ± 0.5%, P < 0.0001), whereas Mucin 1 expression is less in these components (9.0 ± 4.9% vs. 55 ± 8.2%, P = 0.003). These results suggest monoclonal transition from squamous cell carcinoma to adenocarcinoma in lung adenosquamous carcinoma. (Am J Pathol 2000, 156:1289–1298)

Although tumor heterogeneity is a fundamental feature of carcinogenesis and cancer progression, the mechanism by which it occurs remains largely unknown. The heterogeneity of tumor cells is frequently observed in lung cancer. The main pattern consists of a regional distribution of individual cells, similar to their immediate neighbors, whereas more distant cells tend to be similar to their immediate neighbors. According to fundamental concepts concerning the carcinogenesis of lung cancer, field cancerization, and the multistep carcinogenic process, the pathogenesis of these heterogeneous tumor cells would be explained by various carcinogenic stages involving monoclonal or polyclonal expansion. Direct evidence of the clonality of lung cancer cells, however, still remains quite limited, though such information would be essential not only for explaining the process of carcinogenesis and cancer progression, but also for designing successful treatment modalities for heterogeneous tumors.

Adenosquamous carcinoma of the lung, one of the rather rare subtypes of lung cancer, is a typical example of the heterogeneous tumors, containing two distinct components that are either adenocarcinomatous or squamous carcinomatous. The diagnosis of adenosquamous carcinoma should be restricted to carcinomas that show unequivocal squamous differentiation in the form of keratin or intracellular bridges, and unequivocal glandular differentiation in the form of acini, tubules, or papillary structures. According to the most recent World Health Organization classification of lung tumors, a definitive diagnosis of lung adenosquamous carcinoma requires a minimum of 10% of each component in the whole tumor. Although morphological characterizations of both components of adenosquamous carcinoma have been made, no genetic approach to the clonality of adenosquamous carcinoma has yet been attempted. In this study, we performed topographic genotyping and immunohistochemical analysis on 12 adenosquamous carcinoma tumors with a definitive diagnosis, free from either anti-cancer chemotherapy or irradiation therapy before sampling, that would cause genetic changes to the cancer cells. As topographic genotyping, comparative DNA sequences of p53, K-ras, and chromosomal analysis at 9p21 and 9q31–32 were performed on the distinct com-

Supported in part by a grant from Ministry of Education, Science, Sports and Culture of Japan (No. 08670647 to M. E.).

Accepted for publication December 13, 1999.

Address reprint requests to Masahito Ebina, M.D., Ph.D., Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, 4–1, Seiryo, Aoba-ku, Sendai 980-8575, Japan. E-mail: ebinam@idac.tohoku.ac.jp.

1289
ponents in each tumor. p53 mutations occur in approximately one-half of non-small-cell carcinomas at various points within hot spots,\(^1\) supposed as a good marker for detecting the clonality of cancer cells.\(^17,18\) K-ras mutations have been reported in 27 to 46% of adenocarcinomas of the lung, and less or not at all in squamous cell carcinomas.\(^31–33\) Abnormal loci in squamous cell carcinoma, but less in adenocarcinoma of the lung. The immunolocalization of p53 overexpression was compared with the p53 mutations between the distinct components in each tumor. In addition, statistical difference of immunohistochemical expression of the tumor-associated antigens was examined, including the antigens predominantly expressed in adenocarcinomas, such as carcino-embryonic antigen (CEA).\(^25,26\) cancer antigen 19-9 (CA19-9),\(^26–28\) and Mucin 1 (MUC1).\(^29,30\) Squamous cell carcinoma-related antigen (SCC) was also examined, because its rather selective expression in squamous cell carcinomas.\(^31–33\) The expressions of vascular endothelial growth factor (VEGF),\(^34,35\) proliferating cell nuclear antigen (PCNA),\(^36,37\) and p21\(^{WAF1/CIP1}\) were also examined to characterize the two components of these tumors. The degrees of immunoreactivity were quantified according to the distribution of immunoreactive tumor cells among whole tumor cells according to our previous study.\(^36\)

The main purposes of this study were to clarify the clonality of adenosquamous carcinoma of the lung as a typical model of heterogeneous tumors and to elucidate the process of carcinogenesis and cancer progression of these tumors. Such information may suggest successful therapies for heterogeneous tumors.\(^1–3\) The tumors of 12 patients with adenosquamous carcinoma of the lung were obtained at the Hospital of the Institute of Development, Aging and Cancer, Tohoku University (cases 1–8), and the Central Hospital of Aomori Prefecture (cases 9–12). Eight of these tumors (cases 1–4 and 9–12) were resected by surgical operation; the others (cases 5–8) were autopsied (Table 1). Two patients (cases 10 and 11) are without smoking habit; the rest are current or former smokers (Table 1) with the range of Brinkman index for cigarette smoking from 690 to 1400 (958 ± 104, mean ± SEM). Informed consent for genetic analysis of these tumors was obtained from each patient or their families. None of these patients was treated by anti-cancer chemotherapy or irradiation before the tumors were sampled. Metastatic lesions were available in three cases (cases 3, 5, and 8), and were examined by microscopic observation. A pathological diagnosis of adenosquamous carcinoma was based on the WHO Histological Typing of Lung Tumors\(^15\) and checked by at least three independent pathologists. Three to five sampled specimens of each tumor were formalin-fixed and paraffin-embedded, and 10 serial sections 3 μm thick were cut from each block. The first sections were stained with hematoxylin-eosin (H&E), the second sections for periodic acid-Schiff (PAS)-alcian blue staining, and the remaining eight sections were used for immunohistochemical study. Three additional sections 8 μm thick were cut and used for microdissection of the two distinct components of each tumor to extract DNA as described below. Ten primary tumors of lung adenocarcinoma and ten primary tumors of lung squamous cell carcinoma, surgically resected in our hospital, were also used in our pilot study to get control reactions by immunohistochemistry, especially for non-commercially available antibodies against human squamous cell carcinoma-related antigen (F2H7C) and against human MUC1 (MUSEII).

### Materials and Methods

#### Tumors Examined

The tumors of 12 patients with adenosquamous carcinoma of the lung were obtained at the Hospital of the Institute of Development, Aging and Cancer, Tohoku University (cases 1–8), and the Central Hospital of Aomori Prefecture (cases 9–12). Eight of these tumors (cases 1–4 and 9–12) were resected by surgical operation; the others (cases 5–8) were autopsied (Table 1). Two patients (cases 10 and 11) are without smoking habit; the rest are current or former smokers (Table 1) with the range of Brinkman index for cigarette smoking from 690 to 1400 (958 ± 104, mean ± SEM). Informed consent for genetic analysis of these tumors was obtained from each patient or their families. None of these patients was treated by anti-cancer chemotherapy or irradiation before the tumors were sampled. Metastatic lesions were available in three cases (cases 3, 5, and 8), and were examined by microscopic observation. A pathological diagnosis of adenosquamous carcinoma was based on the WHO Histological Typing of Lung Tumors\(^15\) and checked by at least three independent pathologists. Three to five sampled specimens of each tumor were formalin-fixed and paraffin-embedded, and 10 serial sections 3 μm thick were cut from each block. The first sections were stained with hematoxylin-eosin (H&E), the second sections for periodic acid-Schiff (PAS)-alcian blue staining, and the remaining eight sections were used for immunohistochemical study. Three additional sections 8 μm thick were cut and used for microdissection of the two distinct components of each tumor to extract DNA as described below. Ten primary tumors of lung adenocarcinoma and ten primary tumors of lung squamous cell carcinoma, surgically resected in our hospital, were also used in our pilot study to get control reactions by immunohistochemistry, especially for non-commercially available antibodies against human squamous cell carcinoma-related antigen (F2H7C) and against human MUC1 (MUSEII).

#### Microdissection and DNA Extraction

The two different foci in each tumor, determined by subsequent H&E-stained sections, were scraped off individually from three deparaffinized thick sections under microscopic observation. To avoid the contamination of each sample from different foci in one section, the tissue sections were dried up before sampling, and only the foci to be scraped off were wetted using micropipettes. The tissue fragments were collected into microtubes and
digested as previously described.\textsuperscript{30} For the analysis of loss of heterozygosity at 9p21 and 9q31–32, additional DNA samples were extracted from tumor-free lung tissues, which were available in cases 1 to 8 and used for control DNA for each tumor.

**Detecting p53 Mutations**

For detecting p53 mutations within exons 5 to 8, the isolated DNA samples from the two different components of each tumor were amplified using primer sets as described previously.\textsuperscript{41} The amplified polymerase chain reaction (PCR) products were cloned into a pCRII vector (Invitrogen Corp., Carlsbad, CA) and purified through Qiagen Mini Columns (Qiagen Inc., Chatsworth, CA). The mixtures of 20 clones of each DNA sample were sequenced by a dsDNA cycle sequencing system (Gibco BRL, Rockville, MD) using primers end-labeled with \( [\gamma-32P] \) ATP (Amersham Corp., Arlington, IL) according to the manufacturers’ manuals. Mutations were accepted when the genetic alterations were detected in the independent PCR products of the same DNA samples.

**Detecting K-ras Mutations**

The isolated DNA samples from the two different components in each tumor were also analyzed for K-ras mutations at codons 12, 13, and 61 using PCR-restriction fragment length polymorphisms (RFLP) analysis, and direct sequencing. As for codon 12, PCR-primer introduced restriction with enrichment for mutant alleles (PIREMA) was used as described previously.\textsuperscript{21} Briefly, the PCR products (192 bp) were digested with BstNI (TOYOBO, Osaka, Japan), and the digested products were amplified again in the same protocol with the first PCR. As positive controls of the K-ras mutations at these sites, the extracted DNA samples of the cell lines NCI-H358 (TGT) and NCI-H727 (GTT)\textsuperscript{42} were used, in addition to human genomic DNA (Clontech Laboratories, Inc., Palo Alto, CA) as a normal control (GGT). Direct sequencing of DNA samples was also performed for detecting other possible mutations at codon 12, 13, and 61 using a double-strand DNA cycle sequencing system (Gibco BRL) with the primers end-labeled with \( [\gamma-32P] \) ATP (Amersham Corp.) according to a previous study.\textsuperscript{40}

**Microsatellite Analysis at 9p21 and 9q31–32**

Three different DNA samples from each tumor were used for microsatellite analysis, collected independently from the adenocarcinomatous components, squamous carcinomatous components, and tumor-free materials. Microsatellite analysis was omitted in cases 9 to 12, which lacked tumor-free materials. Six microsatellite markers were used in this study to distinguish the chromosomal regions at 9p21 (D9S265, D9S126, D9S259) and 9q31–32 (KM9.1, D9S177) using primer sequences reported before.\textsuperscript{22,24} The primers were end-labeled with 0.2 \( \muCi \) each of \( [\gamma-32P] \) ATP and 0.07 U of T4 polynucleotide kinase (Gibco BRL). PCR amplifications were performed in 10 \( \mul \) reaction volumes, including 50 ng of genomic DNA, 0.6 pg of labeled primer, 50 \( \mumol/L \) of each dNTP (Takara), and 0.5 U of Taq DNA polymerase (Takara). After initial denaturation at 94°C for 3 minutes, 40 cycles of PCR (30 seconds at 94°C, 60 seconds at 50°C, and 60 seconds for 72°C) were performed, with final extension for 10 minutes at 72°C. PCR products were mixed with loading buffer, heat denatured, and electrophoresed in 8% polyacrylamide-urea-formamide gel. The intensity of the radioactivity of the signal was measured using Bio-Imaging Analyzer system (Fuji Film Co., Minami-Ashigara, Japan), and loss of heterozygosity was defined as a reduction in the intensity of one allele in the tumor DNA by at least 50% as compared with the corresponding normal DNA.\textsuperscript{22,24} When both alleles were deleted, the results were confirmed at least twice.

**Immunohistochemistry**

The mouse monoclonal antibody antiseraums used in this study were as follows: anti-human CEA (ZC23, Histofine, Tokyo), anti-human CA19-9 (1116 NS 19-9, CIS bio International, Tokyo), anti-human SCC (F2H7C, kindly provided by Dr. Kato, Yamaguchi University School of Medicine, Yamaguchi, Japan), anti-human VEGF (Santa Cruz Biotechnology, Santa Cruz, CA), anti-human MUC1 (MUSEII, kindly provided by Dr. Imai, Sapporo University, Sapporo, Japan), anti-human p53 (DO-7, Dako Corporation, Carpinteria, CA), anti-human PCNA (PC-10, Dako), and anti-human p21Waf1/Cip1 (Ab-1, Oncogene Science). The optimal dilution of each immunohistochemical reaction was determined by pilot studies as follows: antibodies against CEA and CA19-9 were diluted according to the manufacturer’s recommendations, anti-SCC at 1:100, anti-VEGF at 1:500, anti-MUC1 at 1:50, anti-p53 at 1:20, anti-PCNA at 1:20, and anti-p21Waf1/Cip1 at 1:10. Primary incubation was performed overnight at 4°C with these primary antibodies, and staining was performed using the avidin-biotinylated peroxidase complex technique using Vectastain kits (Vector Laboratories, Burlingame, CA) according to our previous study.\textsuperscript{36} For the reactions with the antibodies against p53 and Waf1, microwave pretreatment was performed using 0.01 mol/L sodium citrate buffer at pH 6.0.

**Quantification and Statistical Analysis**

To quantify the immunoreactive tumor cells, five random sites each per one adenocarcinomatous and one squamous carcinomatous component of the same tumor were color-photographed and observed at 1000× as the final magnification using parallel sampling lines (one nucleus once). The degrees of immunoreactivity of each component were determined by percentage of the positive tumor cells among total tumor cells, positive and negative (approximately 300), according to the quantification methods.\textsuperscript{36} Statistical analysis was performed by \( \chi^2 \) test. The immunoreactivity of cases 9 to 12 was quantified only for the reaction by anti-p53 to determine the overexpression of p53 when more than 10% of the whole tumor cells in each component were positive.\textsuperscript{36}
Results

Light Microscopic Observation

All of the primary tumors examined were found to have both of the well-differentiated adenocarcinomatous and squamous carcinomatous components. The approximate percentages of the areas occupied by the predominant components are shown in Table 1. Each component of these tumors showed a distribution of more than 20% of the whole tumor area, thereby confirming the diagnosis of adenosquamous carcinoma (Figures 1 and 2). The adenocarcinomatous components were often, but not always, positive for PAS-alcian blue staining, with little or no reaction in the squamous components of these tumors (Figure 1b). The tumor cells distributed in the boundary of the two components were observed to have the cytologic features of squamous cell carcinoma, despite forming tubular or papillomatous structures, the characteristic...
features of adenocarcinoma (Figures 1 and 2). Although such intervening areas, referred to as “transitional areas,” were limited in size, they were found in all of the tumors of the twelve cases. Metastatic lesions were available in three cases (3, 5, and 8). Case 3 had lymph node metastasis, which was infiltrated with adenocarcinoma of moderate differentiation (Figure 2f). The autopsied Case 5 had metastasis to multiple organs including the liver, adrenal glands, and lymph nodes, which were infiltrated by adenocarcinomatous components. The metastases to the liver and lymph nodes of case 8, another autopsied case, were also composed only of adenocarcinomatous components (Figure 2g). These metastatic lesions were occupied by homogeneous tumor cells, in contrast to the heterogeneous primary tumors of the lungs.

**p53 Immunoreactivity and p53 Gene Status**

Nuclear staining was observed only in the cells immunoreactive for anti-p53 antibody. p53 overexpression was assumed only when more than 10% of the tumor cells were immunoreactive, according to our previous study.36 Five out of twelve tumors were found to have p53 immunoreactivity. p53 overexpression was found in the lymph nodes with metastasis (f, case 3) and in the liver metastasis (g, case 8), which were invaded by adenocarcinomatous components with moderate differentiation.

Figure 2. Photomicrographs of the adenosquamous carcinomas of case 8 (a, b, g) and Case 3 (c–f) (bar, 100 μm). a: H&E staining. The adenocarcinomatous component (A) showed greater cellular density of cosinophilic staining and nuclear chromatin density than the transitional component (T). b: Squamous carcinomatous components are shown with differentiation (H&E). c: The transitional area (T) was limited in this intervening area of case 3 (H&E). d: Higher expression of CEA was revealed in the adenocarcinomatous components (A), and less prominent in the squamous carcinomatous components (S). Cells with the characteristic features found in the transitional area (T) were distributed apart from the adenocarcinomatous components with expression of CEA. e: The immunohistochemical staining of MUC1 in the adenocarcinomatous compartment (A) is significantly more intense than in the other component (S). f and g: The metastatic tumors showing adenocarcinomatous features overexpressed p53, though both components of the primary sites of these tumors were negative for p53 immunoreactivity. p53 overexpression was found in the lymph nodes with metastasis (f, case 3) and in the liver metastasis (g, case 8), which were invaded by adenocarcinomatous components with moderate differentiation.
components of case 4 contained the same p53 mutation from CAG (glutamine) to CGG (arginine) at codon 167, compared with tumor-free tissues (N). In Case 5, CAC (histidine) was changed to TAC (tyrosine) in exon 8 (at codon 297), and in Case 7, AAC (asparagine) was changed to GAC (aspartic acid) in exon 6 (at codon 210). p53 mutations were not determined in cases 9 and 10 because of the poor quality of DNA samples. Interestingly, no expression of p53 protein was observed and no p53 mutations were detected in either of the components of cases 3 and 8, although the metastatic lesions of these cases overexpressed p53 protein homogeneously and intensively, showing almost all tumor cells positive for p53 protein (Figure 2, f and g).

**K-ras Mutations**

The DNA samples extracted from different foci of the twelve adenosquamous carcinomas were examined for K-ras mutations. No K-ras mutations were detected in either the adenocarcinomatous or squamous carcinomatous portions of each tumor at codons 12 using PCR-RFLP. Figure 3b shows the results of three cases with predominantly adenocarcinomatous components: cases 4 (80%), 5 (60%), and 8 (70%). Complete digestion by BstNI of 192-bp PCR products to 163- and 29-bp fragments showed no mutations were included in these tumors as in the normal control DNA (GGT). The PCR products of the cell lines, NCI-H358 (TGT) and NCI-H727 (GTT), as positive controls of the K-ras mutations, were retained uncut.

**Figure 3.** Comparison of genetic alterations of p53 and K-ras between the two distinct components of adenosquamous carcinomas. **a:** Both components of case 4, adenocarcinomatous (AD) and squamous carcinomatous (SQ), contained the same p53 mutation from CAG (glutamine) to CGG (arginine) at codon 167, compared with tumor-free tissues (N). **b:** Three tumors contained adenocarcinoma as predominant component: cases 4 (80%), 5 (60%), and 8 (70%). Complete digestion by BstNI of 192-bp PCR products to 163- and 29-bp fragments showed no mutations were included in these tumors as in the normal control DNA (GGT). The PCR products of the cell lines, NCI-H358 (TGT) and NCI-H727 (GTT), as positive controls of the K-ras mutations, were retained uncut.

**Figure 4.** Chromosomal abnormalities at 9p21 and 9q31-32 revealed by microsatellite analysis using five markers. D9S265 (a), D9S126 (b), and D9S259 (c) detected chromosomal abnormalities at 9p21, whereas KM9.1 (d), and D9S177 (e) detected 9q31–32. DNA samples extracted from three parts of the lung were used: tumor-free lung tissues (N), adenocarcinomatous components (AD) and squamous carcinomatous components (SQ). Loss of heterozygosity (L), homozygous deletion (HD) or retention (R) of both alleles was determined by densitometry of the polymorphic bands noted by arrows. These results are summarized in Table 2. Case 8 (e) had different abnormalities between the adenocarcinomatous (homozygous deletion) and squamous carcinomatous lesions (homozygous deletion), whereas both alleles were clearly retained in tumor-free foci.

**Table 2.** Chromosomal Status at 9p21 and 9q31-32 in Each Component of Adenosquamous Carcinomas

<table>
<thead>
<tr>
<th>Case no.</th>
<th>9p21 (D9S265)</th>
<th>9p21 (D9S126)</th>
<th>9p21 (D9S259)</th>
<th>9q31-32 (KM9.1)</th>
<th>9q31-32 (D9S177)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>R/R</td>
<td>N/NI</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
</tr>
<tr>
<td>2</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>L/L</td>
<td>R/R</td>
</tr>
<tr>
<td>3</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>N/NI</td>
<td>R/R</td>
</tr>
<tr>
<td>4</td>
<td>L/L</td>
<td>R/R</td>
<td>N/NI</td>
<td>R/R</td>
<td>N/NI</td>
</tr>
<tr>
<td>5</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
</tr>
<tr>
<td>6</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>L/L</td>
<td>R/R</td>
</tr>
<tr>
<td>7</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
<td>R/R</td>
</tr>
<tr>
<td>8</td>
<td>R/R</td>
<td>R/R</td>
<td>HD/L</td>
<td>R/R</td>
<td>R/R</td>
</tr>
</tbody>
</table>

AD, adenocarcinomatous component; SQ, squamous carcinomatous component; R, retention of both alleles; L, loss of heterozygosity; HD, homozygous deletion; NI, not informative.
Microsatellite Analysis of Chromosome 9

The microsatellite regions at 9p21, marked by D9S265, D9S126, and D9S259, and at 9q31–32, marked by KM9.1 and D9S177, were compared between the different components of each tumor. Control DNA samples taken from a tumor-free locus are required to show chromosomal alterations, but were available only in cases 1 to 8. Four of these eight cases contained heterozygous or homozygous deletions detected by the five markers examined (Table 2, Figure 4). The deletions occurred more frequently in 9q31–32 (4/28, 14.3%) than in 9p21 (4/44, 9.1%). The identical abnormality (heterogeneous deletion) was found in the two components in three cases. Only one case, Case 8, was found to have different abnormalities in the two distinct components. In the adenocarcinomatous component of Case 8, both alleles were lost (homozygous deletion) at D9S259, whereas only a heterozygous deletion was detected in the squamous carcinomatous component (Figure 4c). These abnormalities were confirmed by independent PCR reactions at least twice.

Quantitative Analysis of Immunohistochemistry

The distributions of immunoreactive tumor cells among the whole tumor cells were quantified by calculating the percentage of positive tumor cells in each component, and analyzed by \( \chi^2 \) test. The similarities between the different components of each tumor were revealed to be 79.7% (51/64) in coincident immunoreactivity. Higher immunoreactivity in the adenocarcinomatous components was revealed by the expression of CEA in cases 3 (Figure 2d) and 8, CA19-9 in cases 2 (Figure 1h), 5, and 6, MUC1 in case 3 (Figure 2e), and VEGF in case 2. In 7 of 8 cases (87.5%), more than 50% positive tumor cells in the adenocarcinomatous component were found to have squamous cell carcinoma-related antigen (SCC). The SCC immunoreactivity in the adenocarcinomatous component was much higher than the average of SCC immunoreactivity in 10 lung adenocarcinomas by our pilot study (57.2 ± 5.8% versus 1.0 ± 0.5%, mean ± SEM, \( P < 0.0001 \)), close to the SCC expressions in squamous components of these tumors (57.0 ± 9.7%, \( P = 0.988 \)) and in 10 lung squamous cell carcinomas.
(43.4 ± 9.0%, \( P = 0.241 \)). The intervening tumor cells in the transitional areas between the two distinct components were also reactive with anti-SCC antigen, as shown in Figure 1g. In contrast, the expression of MUC1, which is 55.3 ± 8.2% in 10 lung adenocarcinomas and 1.25 ± 0.71% in 10 lung squamous cell carcinomas by our pilot study, was very low (<10% positive) in 7 adenocarcinomatous components. The mean MUC1 expression of 8 adenocarcinomatous components was 9.04 ± 4.9%, significantly lower than that of 10 lung adenocarcinomas (\( P = 0.003 \)). The MUC1 expression of squamous carcinomatous components was 4.30 ± 1.08%. Higher PCNA immunoreactivity was seen in the squamous cell carcinomatous components in three cases (1, 2, and 6), but only in the adenocarcinomatous lesions in one case, case 8.

Discussion

It is widely accepted that cancer results from the accumulation of mutations in the genes that directly control cell birth or cell death.\(^4\)\(^3\) Such genetic instabilities of tumor cells are partly induced by the selective conditions in the tumor environment, including aberrant humoral, cell-substratum, and cell-cell interactions, that give rise to clonal expansion, allowing the tumor cell with the mutation to overtake its sister cells.\(^4\)\(^3\) In this context, heterogeneity is a frequent event in cancer, which may happen by clonal selection\(^4\)\(^4\) of the appropriate cells in the tumor environment.

Concerning the histogenesis of adenosquamous carcinoma, several possible pathways have been proposed, divided into monoclonal or polyclonal pathways. Monoclonality consists of a transformation from one component to the other, and the polyclonal pathway is assumed to result from a collision of two tumors, each encountering the other as an independent component.\(^1\)\(^3\)\(^,\)\(^4\)\(^6\) Our two major findings, the similarities of the two distinct components by genetic and immunohistochemical analysis and the major characteristics of squamous cell carcinomas, were detected even in the adenocarcinomatous components, strongly suggesting a transition from the squamous cell carcinomatous components. The transitional areas, distributed between the two distinct components in all of the tumors examined in this study, were occupied by tumor cells retaining the characteristics of both adenocarcinoma and squamous cell carcinoma. The existence of transitional areas in the intervening region between distinct components was partly suggested by morphological studies.\(^4\)\(^6\)\(^,\)\(^4\)\(^7\) Hammond et al described the frequent concurrence of adenocarcinoma and squamous cell carcinoma arising separately in the small lesions in their hamster lung cancer models, but they also suggested the possibility that these cells arose from bipotential cells manifesting two separate histological patterns.\(^4\)\(^7\) Such previous studies were based mainly on morphological observations and would not, therefore, address the problem of the clonality of heterogeneous cells.

In this study, we revealed the genetic similarities of the different components of each tumor. The immunoreactiv-

ity of p53 was detected in five of twelve tumors (42%) examined, and no statistically significant difference was found in the degrees of intensity or distribution of p53 expression between each component of these tumors. The same point mutation was detected in the distinct components of each tumor of the three cases with p53 overexpression, suggesting the early occurrence of the p53 mutations in these tumors. We also found a coincidence between the two components in the gene status of K-ras (100%) at codons 12, 13, and 61, and the chromosomal status except only one case at one locus. These findings strongly support the hypothesis of a monoclonal expansion of a single mutant progenitor cell clone, which expands over time to populate widespread areas of the respiratory tract.

We sought to determine the possible existence of a progenitor component in the adenosquamous carcinomas. No K-ras mutations were detected at codons 12, 13, and 61 in any of the components of the 12 tumors examined in this study, and there are also previous reports that showed no K-ras mutations in the adenosquamous carcinomas of the lung.\(^1\)\(^9\)\(^,\)\(^2\)\(^0\) This lack of K-ras mutations even in the adenocarcinomatous components conflicts with the numerous reports showing frequent K-ras mutations in usual adenocarcinomas of the lung.\(^1\)\(^9\)\(^–\)\(^2\)\(^1\)\(^,\)\(^4\)\(^3\) By immunohistochemical comparison, moreover, we found higher expression levels of SCC and lower expression of MUC1 in these adenocarcinomatous compartments than in usual adenocarcinomas of the lung.\(^3\)\(^0\)\(^,\)\(^3\)\(^1\)\(^,\)\(^3\)\(^3\) The absence of K-ras mutations and the immunohistochemical characteristics of the adenocarcinomatous components strongly suggested that the squamous compartment was the original lesion of these adenosquamous carcinomas. The progressed abnormality found in the adenocarcinomatous component of case 8 at 9p21, D9S259, may also support our hypothesis of a transition from the squamous carcinomatous component to the adenocarcinomatous component, caused by subsequent genetic alterations.

Clinicopathological studies showing a poorer prognosis for adenosquamous carcinomas of the lung than adenocarcinoma and squamous cell carcinomas\(^4\)\(^8\)\(^–\)\(^5\)\(^0\) suggest that adenosquamous carcinomas may originate from progenitor cells different from those of homogeneous tumor cells, acquiring bipotential differentiation. The most likely precursor for squamous cell carcinoma of the lung is squamous metaplasia originating from basal cell hyperplasia.\(^1\)\(^0\)\(^,\)\(^5\)\(^1\) McDowell et al\(^5\)\(^2\) proposed the mucous secretory cell as the major proliferating component, with proliferation of these cells leading ultimately to invasive carcinomas that can become differentiated into either squamous cell carcinoma, adenocarcinoma, or combined adenosquamous carcinoma. Considering that atypical adenomatous hyperplasia is now more widely accepted as the precursor lesion of peripheral adenocarcinomas\(^1\)\(^0\)\(^,\)\(^5\)\(^3\)\(^–\)\(^5\)\(^5\) and in which K-ras mutations are detected as in adenocarcinomas,\(^5\)\(^6\) it is unlikely that a transition from adenocarcinoma to squamous cell carcinoma occurs. The biological meaning of differentiation into distinct components from bipotential stem cells might be explained by the hypothesis of Mabry et al, according to which admixtures of the phenotypes of lung cancer may
mimic the transitions of normal cellular differentiation in bronchial mucosa.  

The three metastatic tumors were consisted of adenocarcinoma with a higher grade of differentiation, which is consistent with previous studies showing higher frequencies of adenocarcinoma invading metastatic lesions of adenosquamous carcinomas.  

These results also support the notion of adenocarcinomatous components acquiring invasive potency. The evidence revealed in the present study that the metastatic lesions of two tumors without p53 overexpression acquired intense expression of p53 protein may be one example of accumulating abnormalities.

Higher immunoreactivity of CEA, CA19-9, MUC1, and VEGF, shown in some adenocarcinomatous components of these tumors, does not imply the origin of the heterogeneous tumor cells because transcriptional changes, either gain or loss, could happen during differentiation. Although the expression of PCNA was significantly higher in three squamous components and in one adenocarcinomatous component, higher expression of PCNA is not always correlated with excessive proliferation in non-small-cell lung cancer because of abnormal cell-cycle regulation and/or prolonged half life of PCNA.

In conclusion, we investigated the clonal expansion in the carcinogenic process of adenosquamous carcinoma, and the results suggest that the consistent genetic abnormalities that are retained within both components may be targeted for successful treatment.

References

35. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox


